 FLORHAM PARK, N.J., Nov. 09, 2020 GLOBE NEWSWIRE -- Cellectar Biosciences, Inc. NASDAQ: CLRB, a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. 